Is Eisai Co., Ltd. (ESALF) a Buy, Sell, or Hold?
OTC : ESALF
Eisai Co., Ltd. — News
$27.54 USD
$0 (0.0%)
- Volume
- 1
- Average Volume
- 75
- Market Capitalization
- $7.77B
- P/E Ratio
- 29.97
- Dividend Yield
- 3.56%
- Price Target
- Year High
- $35.83
- Year Low
- $23.88
- Day High
- —
- Day Low
- —
- Payout Ratio
- $1.07
- Current Ratio
- $2.24
| Source | Headline |
|---|---|
|
Eisai Co., Ltd. (ESAIY) Q1 2027 Earnings Call Transcript
Eisai Co., Ltd. (ESAIY) Q1 2027 Earnings Call Transcript seekingalpha.com - 2026-08-03 14:59:54 |
|
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug
The U.S. FDA on Monday approved an at-home starting dose of Eisai's and Biogen's Alzheimer's drug, allowing some patients to begin therapy with injections administered by themselves or a caregiver. reuters.com - 2026-07-13 15:02:12 |
|
Eisai Co., Ltd. (ESAIY) Analyst/Investor Day Transcript
Eisai Co., Ltd. (ESAIY) Analyst/Investor Day Transcript seekingalpha.com - 2026-05-25 10:47:04 |
|
BioArctic Interim Report for the period January - March 2026
STOCKHOLM, May 20, 2026 /PRNewswire/ -- Strong financial performance with commercial milestone reached Events during the first quarter 2026 Leqembi® Iqlik™ (subcutaneous formulation) was granted Priority Review by the FDA in the US for initiation treatment Eisai submitted an expanded application for EU approval of intravenous maintenance treatment with Leqembi administered every four weeks The application for marketing authorization for subcutaneous initiation treatment with Leqembi was granted Priority Review in China New long-term and real-world data for Leqembi, presented at the AD/PD™ conference in Copenhagen, showed that patients choose to remain on treatment over a long period and that the disease-slowing treatment effect was sustained for up to four years of treatment Sales of Leqembi exceeded EUR 500 M during Eisai's financial year 2025 (April 2025 – March 2026), triggering a second sales-related milestone payment of EUR 20 M Events after the end of the period The Swedish NT Council announced that it currently does not recommend the introduction of Leqembi in Swedish healthcare The FDA has extended the review period for the supplemental Biologics License Application (sBLA) for Leqembi® Iqlik™ by three months. The application concerns subcutaneous administration of Leqembi as an initiation treatment for early Alzheimer's disease. prnewswire.com - 2026-05-20 03:30:00 |
|
Eisai Co., Ltd. (ESAIY) Q4 2026 Earnings Call Transcript
Eisai Co., Ltd. (ESAIY) Q4 2026 Earnings Call Transcript seekingalpha.com - 2026-05-15 12:50:46 |
